Kevin Guan

Kevin Guan

Spoken Languages
Mandarin Cantonese English
Kevin Guan
Hong Kong
+852 3658 5391

Kevin Guan is an associate in the firm’s Business Law department and Life Sciences group. Kevin has experience in mergers and acquisitions, venture capital, cross-border licensing, joint ventures, China inbound and outbound transactions, foreign direct investments, and general corporate matters.

Prior to joining Goodwin in 2021, Kevin was most recently the in-house counsel at a tech startup in Hong Kong and previously practiced in the Shanghai office of a major US law firm. Kevin is a native Mandarin and Cantonese speaker and is fluent in English.


Kevin’s experience includes representing:

  • AccuGen Group in its Series Seed Plus financing
  • Allogene Therapeutics in its collaboration and license agreement with and equity investment into Antion Biosciences
  • Apollomics, Inc. in its license agreement with Edison Oncology
  • Biotheus, Inc. in its licensing and collaboration transaction with Hansoh for its EGCR/MET bispecific antibody
  • BridGene Biosciences in its Series A financing
  • DualityBio in its global strategic partnership with BioNTech on two ADC programs
  • HiFiBiO Therapeutics in its Series D financing
  • HighTide Therapeutics in its Series C financing
  • HTDK Group in its collaboration transaction with Sofwave Medical.
  • Jemincare in its licensing transaction with Genentech for its novel oral androgen receptor degrader.
  • Neuro3 Therapeutics in its acquisition of the exclusive worldwide right to develop and commercialize clinical stage KCNQ2 from Lundbeck
  • Novita Pharmaceuticals in its license agreement with China Resources Double-Crane
  • Novo Holdings in its acquisition of Ritedose Corporation  
  • OrbiMed in its joint venture’s licensing transaction with Kinnate Biopharma
  • Seagen Inc. in its licensing and collaboration transaction with Zai Lab for TIVDAK®
  • Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. in its licensing and collaboration transaction with Merck for seven pre-clinical ADC programs
  • SK Biopharmaceuticals in its launch of Ignis Therapeutics, a biotech joint venture with 6 Dimensions Capital and other notable investors 
  • Numerous biotech startups in their formation and early-stage financing
  • Numerous venture capital funds in their early-stage investments in biotech startups
  • Eight Roads Ventures in its venture capital investments in numerous China-based startups* 
  • MedBanks Network Technology Co., Ltd. in its Series B and Series C financing*
  • Tongfu Microelectronics Co., Ltd. in its acquisition of Advanced Micro Devices, Inc.’s two semiconductor packaging factories in Asia*
  • VcanBio Cell & Gene Engineering Corp., Ltd. in its acquisition of OriGene Technologies, Inc.*

*Denotes experience prior to joining Goodwin.




Columbia Law School

(Harlan Fiske Stone Scholar)


Sun Yat-sen University


Sun Yat-sen University



  • New York
  • HK Registered Foreign Lawyer (New York)